The engineered probiotics for the treatment of chronic diseases: A systematic review

Barati, Meisam; Jabbari, Masoumeh; Ghavidel, Afshin Abdi; Nikmehr, Payman; Arzhang, Pishva; Aynehchi, Aydin; Babashahi, Mina; Mosharkesh, Erfan; Roshanravan, Neda; Shabani, Mahdi; Davoodi, Sayed Hossein

doi:10.1111/jfbc.14343

Cited by 3 publications

(2 citation statements)

References 65 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the improvement of the knowledge of the interaction between cancer and bacteria, as well as among chronic inflammation, cancer, and immune modulation, could lead in the future toward personalized approaches based on less invasive and more sensitive therapies, such as photodynamic therapy, gene therapy, probiotic therapy, engineered vaccines, or monoclonal antibodies [ 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 ].…”

Section: Discussionmentioning

confidence: 99%

Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review

Menditti,

Santagata,

Imola

et al. 2023

JPM

View full text Add to dashboard Cite

For decades, oral squamous cell carcinoma (OSCC) has been one of the most prevalent and mortal cancers worldwide. The gold standard for OSCC diagnosis is still histopathology but this narrative multidisciplinary review has the aim to explore the literature about conventional OSCC prognostic indicators related to the pTNM stage at the diagnosis such as the depth of invasion and the lymphovascular invasion associated with distant metastasis as indicators of poor life expectancy. Despite its multifactorial nature and recognizable precursors, its diagnosis at the early stages is still challenging. We wanted to highlight the importance of the screening as a primary weapon that a stomatologist should consider, intercepting all at-risk conditions and lesions associated with OSCC and its early stages. This narrative review also overviews the most promising imaging techniques, such as CT, MRI, and US-echography, and their application related to clinical and surgical practice, but also the most-investigated prognostic and diagnostic tissue and salivary biomarkers helpful in OSCC diagnosis and prognostic assessment. Our work highlighted remarkable potential biomarkers that could have a leading role in the future. However, we are still far from defining an appropriate and concrete protocol to apply in clinical practice. The hope is that the present and future research will overcome these limitations to benefit patients, clinicians, and welfare.

show abstract

Section: Discussionmentioning

confidence: 99%

Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review

Menditti,

Santagata,

Imola

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…For example, gut microbiota alteration can cause various metabolic diseases ( Hur and Lee, 2015 ). Thus, novel strategies using engineered probiotics (EPs) for the treatment of various diseases, including metabolic disorders and inborn errors of metabolism, need to be developed ( Riglar et al, 2017 ; Barati et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Engineered Probiotics for the Management of Congenital Metabolic Diseases: A Systematic Review

Barati,

Mosharkesh,

Tahmassian

et al. 2024

Prev. Nutr. Food Sci.

Self Cite

View full text Add to dashboard Cite

Engineered probiotics (EPs) can be used to treat/manage chronic and congenital diseases. However, to the best of our knowledge, no systematic review has evaluated the effects of EPs on congenital metabolic disorders in murine models and human subjects. Thus, the present study systematically reviewed interventional studies that assessed the effects of EPs on congenital metabolic disorders. PubMed, Web of Science, and Scopus databases were searched up to February 2023 to retrieve related publications. Seventy-six articles were obtained in the primary step. After screening the titles/abstracts based on the inclusion and exclusion criteria, 11 papers were included. Finally, only seven articles were included after performing full-text evaluation. The included articles evaluated the effects of EPs on managing phenylketonuria (PKU, n=4) and hyperammonemia (n=3). Moreover, these studies examined mice and/or rats (n=6), monkeys (n=1), and humans (n=2). Studies on EPs and hyperammonemia revealed that some wild strains such as Lactobacillus plantarum have an innate ammonia-hyper-consuming potential; thus, there was no need to manipulate them. However, manipulation is needed to obtain a phenylalanine-metabolizing strain. In conclusion, EPs can be used to manage or treat congenital metabolic diseases including PKU.

show abstract

Microbiota and Recurrent Pregnancy Loss (RPL); More than a Simple Connection

Garmendia,

De Sanctis,

Hajdúch

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Recurrent Pregnancy Loss (RPL) affects 1–2% of women, and its triggering factors are unclear. Several studies have shown that the vaginal, endometrial, and gut microbiota may play a role in RPL. A decrease in the quantity of Lactobacillus crispatus in local microbiota has been associated with an increase in local (vaginal and endometrial) inflammatory response and immune cell activation that leads to pregnancy loss. The inflammatory response may be triggered by gram-negative bacteria, lipopolysaccharides (LPS), viral infections, mycosis, or atypia (tumor growth). Bacterial structures and metabolites produced by microbiota could be involved in immune cell modulation and may be responsible for immune cell activation and molecular mimicry. Gut microbiota metabolic products may increase the amount of circulating pro-inflammatory lymphocytes, which, in turn, will migrate into vaginal or endometrial tissues. Local pro-inflammatory Th1 and Th17 subpopulations and a decrease in local Treg and tolerogenic NK cells are accountable for the increase in pregnancy loss. Local microbiota may modulate the local inflammatory response, increasing pregnancy success. Analyzing local and gut microbiota may be necessary to characterize some RPL patients. Although oral supplementation of probiotics has not been shown to modify vaginal or endometrial microbiota, the metabolites produced by it may benefit patients. Lactobacillus crispatus transplantation into the vagina may enhance the required immune tolerogenic response to achieve a normal pregnancy. The effect of hormone stimulation and progesterone to maintain early pregnancy on microbiota has not been adequately studied, and more research is needed in this area. Well-designed clinical trials are required to ascertain the benefit of microbiota modulation in RPL.

show abstract

The engineered probiotics for the treatment of chronic diseases: A systematic review

Cited by 3 publications

References 65 publications

Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review

Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review

Engineered Probiotics for the Management of Congenital Metabolic Diseases: A Systematic Review

Microbiota and Recurrent Pregnancy Loss (RPL); More than a Simple Connection

Contact Info

Product

Resources

About